About OrthoTrophix
OrthoTrophix is a Healthcare company based in Oakland (United States) founded in 2011. It develops and commercializes therapies for hard tissue diseases like osteoarthritis. It operates on a B2B model. OrthoTrophix offers products and services including TPX-100. Its focus areas include Life Sciences, Drug Development, Hard Tissue Therapies and Bone and Cartilage Conditions. Its legal entity is OrthoTrophix, Inc. Similar companies include Horizon Therapeutics, Augmenix, Histogenics, Osteal Therapeutics and AmacaThera and 5 more; 9 of its 10 listed similar companies have raised funding.
Company details
OrthoTrophix is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for conditions affecting bone and cartilage, particularly osteoarthritis. Their primary effort involves creating a first-in-class drug, TPX-100, which has shown safety and efficacy in clinical trials for improving joint function. Based in the United States, they engage in research, licensing agreements, and presentations at industry events to advance their compounds.
- Headquarters Oakland, United States
- SectorsHealthcare
- Email••••••••
- Website orthotrophix.com
- Legal Name Orthotrophix, Inc.
Products & Services of OrthoTrophix
OrthoTrophix offers a comprehensive portfolio of products and services, including TPX-100.
Compound for treating knee osteoarthritis with improved function and safety.
Similar companies to OrthoTrophix
OrthoTrophix has 10 listed similar companies in our database, 9 of them funded. They include Horizon Therapeutics, Augmenix, Histogenics, Osteal Therapeutics and AmacaThera, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| augmenix.com | 2008 | Waltham, United States | $46.6M | 153 | Hydrogel spacers are provided for prostate cancer radiation therapy. | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| ostealtx.com | 2013 | San Clemente, United States | $110.8M | – | Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections | |
| amacathera.ca | 2015 | Toronto, Canada | $14.22M | – | Injectable hydrogel platform developed for therapeutic medical applications. | |
| angitiabio.com | 2018 | Woodland Hills, United States | $276M | – | Drugs for muscle, bone, and joint diseases are developed. | |
| enobia.com | 1997 | Quebec, Canada | $138.52M | – | Therapies for genetic metabolic bone disorders are developed. | |
| fibrocell.com | 1995 | Exton, United States | $34.66M | – | Developer of autologous cell and gene therapies for diseases of the skin, connective tissue and joints | |
| zetagen.com | 2017 | Syracuse, United States | $20.35M | – | Small molecule therapeutics for bone regeneration are developed. | |
| biomimetics.com | 2000 | Franklin, United States | – | 58 | Regenerative therapeutics for musculoskeletal injuries are developed and commercialized. |
Detailed similar companies of OrthoTrophix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as OrthoTrophix (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Orthotrophix
Complete news archive for OrthoTrophix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OrthoTrophix
OrthoTrophix was founded in 2011.
OrthoTrophix is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
OrthoTrophix is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for conditions affecting bone and cartilage, particularly osteoarthritis. Their primary effort involves creating a first-in-class drug, TPX-100, which has shown safety and efficacy in clinical trials for improving joint function. Based in the United States, they engage in research, licensing agreements, and presentations at industry events to advance their compounds.
OrthoTrophix's top competitors include Horizon Therapeutics, AmacaThera and ZetaGen.
OrthoTrophix offers TPX-100.
OrthoTrophix operates through Orthotrophix, Inc..